logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy set to benefit from Large Hadron Collider spin-off

Dr Michael Sinclair, CEO of Advanced Oncotherapy (LON:AVO), tells Proactive Investors his firm is uniquely placed to exploit a strand of particle physics from the Cern Laboratories to combat cancer tumours. Mike says that AVO is working towards producing proton beam therapy machines, at a fraction of the cost of existing machines, using its own patented technology.

Quick facts: Advanced Oncotherapy PLC

Price: 38.9805 GBX

LSE:AVO
Market: LSE
Market Cap: £92.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

2 min read